Epsilon toxin–producing <i>Clostridium perfringens</i> colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege

Yinghua Ma; David Sannino; Jennifer R. Linden; Sylvia Haigh; Baohua Zhao; John B. Grigg; Paul Zumbo; Friederike Dündar; Daniel Butler; Caterina P. Profaci; Kiel Telesford; Paige N. Winokur; Kareem R. Rumah; Susan A. Gauthier; Vincent A. Fischetti; Bruce A. McClane; Francisco A. Uzal; Lily Zexter; Michael Mazzucco; Richard Rudick; David Danko; Evan Balmuth; Nancy Nealon; Jai Perumal; Ulrike Kaunzner; Ilana L. Brito; Zhengming Chen; Jenny Z. Xiang; Doron Betel; Richard Daneman; Gregory F. Sonnenberg; Christopher E. Mason; Timothy Vartanian

doi:10.1172/JCI163239

Epsilon toxin–producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege

Yinghua Ma,¹ David Sannino,¹ Jennifer R. Linden,¹ Sylvia Haigh,¹ Baohua Zhao,¹ John B. Grigg,^2,3,4,5 Paul Zumbo,^6,7 Friederike Dündar,^6,7 Daniel Butler,⁷ Caterina P. Profaci,⁸ Kiel Telesford,¹ Paige N. Winokur,⁹ Kareem R. Rumah,¹⁰ Susan A. Gauthier,¹¹ Vincent A. Fischetti,¹⁰ Bruce A. McClane,¹² Francisco A. Uzal,¹³ Lily Zexter,¹¹ Michael Mazzucco,¹ Richard Rudick,¹⁴ David Danko,⁷ Evan Balmuth,¹ Nancy Nealon,¹¹ Jai Perumal,¹¹ Ulrike Kaunzner,¹¹ Ilana L. Brito,¹⁵ Zhengming Chen,¹⁶ Jenny Z. Xiang,¹⁷ Doron Betel,^6,7 Richard Daneman,⁸ Gregory F. Sonnenberg,^2,3,4,5 Christopher E. Mason,^1,7 and Timothy Vartanian^1,5,11

Authorship note: YM, DS, and JRL contributed equally to this work.

Published February 28, 2023 - More info

View PDF

Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models

Anthony T. Reder

Commentary

Abstract

Multiple sclerosis (MS) is a complex disease of the CNS thought to require an environmental trigger. Gut dysbiosis is common in MS, but specific causative species are unknown. To address this knowledge gap, we used sensitive and quantitative PCR detection to show that people with MS were more likely to harbor and show a greater abundance of epsilon toxin–producing (ETX-producing) strains of C. perfringens within their gut microbiomes compared with individuals who are healthy controls (HCs). Isolates derived from patients with MS produced functional ETX and had a genetic architecture typical of highly conjugative plasmids. In the active immunization model of experimental autoimmune encephalomyelitis (EAE), where pertussis toxin (PTX) is used to overcome CNS immune privilege, ETX can substitute for PTX. In contrast to PTX-induced EAE, where inflammatory demyelination is largely restricted to the spinal cord, ETX-induced EAE caused demyelination in the corpus callosum, thalamus, cerebellum, brainstem, and spinal cord, more akin to the neuroanatomical lesion distribution seen in MS. CNS endothelial cell transcriptional profiles revealed ETX-induced genes that are known to play a role in overcoming CNS immune privilege. Together, these findings suggest that ETX-producing C. perfringens strains are biologically plausible pathogens in MS that trigger inflammatory demyelination in the context of circulating myelin autoreactive lymphocytes.

Introduction

Multiple sclerosis (MS) lesions are centered on postcapillary venules (1, 2), and impairment of blood-brain barrier (BBB) function is considered the earliest event in lesion evolution, paving the way for entry of myelin autoreactive lymphocytes (2–4). MS disease initiation, and thus lesion formation, is believed to require an environmental trigger in a genetically susceptible individual, but biologically plausible environmental agents responsible for lesion induction have been elusive (5, 6). Recent studies have consistently identified dysbiosis in patients with MS, based on taxonomic and functional features of the gut microbiome (7–19). Transfer of gut microbiota from identical twins discordant for MS revealed a significantly higher incidence of autoimmunity in mice receiving microbiota from MS-affected mice compared with their healthy twins (9). Several studies in mice provide compelling evidence that the MS gut microbiome harbors microbes that directly act on adaptive immune cells to enhance or suppress autoimmunity (9, 12, 20–25). Epsilon toxin (ETX) produced by C. perfringens is a unique candidate environmental trigger for MS because this bloodborne neurotoxin specifically targets CNS endothelial cells, leading to disruption of BBB integrity (26).

C. perfringens is a gram-positive anaerobe categorized into 7 toxinotypes based on production of 1 or more of 6 major toxins (27). The type B and D strains carry the plasmid-encoded ETX gene (etx) (27). In the gastrointestinal tract of mammals, C. perfringens types B and D exist in the small intestine, where they produce ETX episodically during log-phase growth (28–30). Human exposure to C. perfringens strains is broad; they are present in our food chain and pets, and are found in multiple ecological niches including farm runoff, sewage, marine sediment, soil, and the gastrointestinal tracts of fish, birds, and mammals (31–43). As a spore-forming anaerobe, once C. perfringens enters an environment it tends to persist due to the spores’ resistance to heat, chemicals, radiation, and pressure (44–46). Following environmental exposure and oral ingestion, colonization of the small intestine is thought to be dependent on host genetics, microbiome composition, and additional factors such as prior antibiotic use (47).

ETX is a member of the aerolysin-family of pore-forming toxins (48–50). ETX is synthesized as a 32.9 kDa inactive protoxin that is cleaved in the gut by host serine proteases and carboxypeptidases (48, 51), or, occasionally, by bacterially derived lambda protease, into a 27 kDa active toxin (48, 52). The ETX monomer crosses the small intestine without causing injury or enteritis (53). We identified the myelin and lymphocyte protein (MAL) as the receptor for ETX (54), which is required for binding and for all known biologic activity (26, 54–58). MAL is localized to lipid rafts, and ETX binding to MAL brings monomers into proximity, favoring self-assembly into a heptameric prepore complex that then inserts into the plasma membrane of host cells (59–61). In the bloodstream, ETX has access to all vascularized tissues, but its binding is restricted to CNS endothelial cells, since they are enriched for expression of the ETX receptor, MAL (26). In vivo, ETX induces BBB permeability (26, 56, 62–64).

In this report, we present evidence that ETX-producing strains of C. perfringens can function as environmental triggers for MS. To characterize the possible role of ETX in MS, we (a) identified an association between ETX-producing strains of C. perfringens and MS in clinical samples; (b) found that people with MS have increased abundance of ETX-producing strains of C. perfringens in their gut microbiome compared with healthy controls; (c) showed that ETX was sufficient to induce multifocal, inflammatory demyelination in the context of active immunization with MOG_35-55; (d) demonstrated that ETX-induced inflammatory demyelination in active EAE more closely resembled the lesion distribution observed in MS when compared with the traditional PTX model; and (e) found that, in CNS endothelial cells, ETX induced expression of genes known to overcome CNS immune privilege.

Results

The MS gut microbiome harbors ETX-producing C. perfringens strains. Based on a statistical power calculation (Methods), 62 participants were recruited under the IRB protocol: Harboring the Initial Trigger of Multiple Sclerosis (HITMS), consented, and received instruction on self-collection of fecal samples. Participants who were healthy controls (HCs) and those with MS were matched for age, gender, BMI, location of residence at time of fecal sample donation, and ancestry or ethnicity (Supplemental Table 1 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI163239DS1). Inclusion into the MS arm of the study required a diagnosis of confirmed MS based on the 2010 revised McDonald criteria (65). Participants having a first- or second-degree relative with a diagnosis of MS or a clinically isolated syndrome were excluded from the HC arm. Full inclusion and exclusion criteria are detailed in the Methods and Supplemental Methods.

We recognized that ETX-producing strains of C. perfringens would likely be in relative low abundance in human fecal samples based on the results of previous surveys (57, 66) and because the ecological niche of these mucosal-adherent bacteria is in the small intestine (67), a site known to be vastly underrepresented in fecal samples (68, 69). Low abundance in fecal samples likely renders C. perfringens types B or D undetectable by metagenomics sequencing commonly utilized in MS microbiome studies (9, 12). We therefore utilized PCR, a more sensitive approach for gene detection than shot-gun metagenomics, to examine whether the etx gene is present in human gut microbiota. We used a density gradient centrifugation, Nycodenz, in our study because separation of bacteria from nonmicrobial fecal matter removes PCR inhibitors, provides a more accurate representation of bacterial composition, and enhances recovery of the phylum Bacillota (Firmicutes), and, in particular the class Clostridia (70) (Figure 1A). Our initial screen detected an occurrence of etx in 61% of MS patients and 13% of controls (Figure 1B; see complete unedited blots in the supplemental material.). To confirm etx-positive study participants, we conducted an independent PCR, targeting a different region of the etx gene (Figure 1C). The identities of all PCR products were verified by Sanger sequencing. The cpa/plc gene, common to all C. perfringens strains, and the 16S ribosomal RNA gene specific to C. perfringens, were also detected in those etx⁺ participants (Figure 1C), as anticipated, since only C. perfringens are known to naturally encode the etx gene. A Fisher’s exact test of independence showed that etx was significantly associated with disease status (MS versus HC), with P = 0.0002 (Figure 1D). The odds ratio of etx-positivity, comparing people with MS and people categorized as HCs, was 10.7, with a 95% CI of 2.9871–38.2381 and P = 0.0003. We further conducted a multivariable logistic regression to determine if disease status (MS diagnosis or healthy control) was associated with etx status (etx^– or etx⁺), independent of sex, with or without stratification by treatment status (treated or not treated). We found that the disease status was independently associated with etx status, even when adjusting for sex. In addition, the disease status (MS versus HC), with or without treatment, was independently associated with etx status, adjusting for sex (Supplemental Table 2).

Figure 1

Prevalence of etx in the gut microbiome of people with MS and people who were HCs. (A) Workflow of the experimental setup. Fecal bacteria were purified by density gradient centrifugation in a Nycodenz solution. (B) Initial screen by PCR targeting the 3′-terminal sequence of etx (542 bp) detected more frequent presence of etx in people with MS compared with people who were HCs. (C) Confirmatory assays for etx⁺ participants from the initial screen (B) using PCR for C. perfringens-specific genes. PCRs targeting the 5′-terminal sequence of etx (679 bp) confirmed the initial detection results. Detection of C. perfringens-specific 16S rRNA and the chromosomally located alpha toxin (cpa/plc) gene present in all C. perfringens strains corroborates the source of the etx gene. Participants labeled in red are included as known etx^– samples from B and included for comparison. Reference strains including C. perfringens type B (ATCC3626), type D (FD203), and type F (ATCC12915) were included as additional controls. Types B and D are etx-harboring strains and type F is negative for etx. Types B, D, and F are all positive for cpa/plc and C. perfringens-specific 16S rRNA. (D) Statistical analysis of etx frequency by Fisher’s exact test. Similar results were achieved in 3 independently repeated PCR experiments using the same people.

The prevalence of fecal etx positivity in our analysis was consistent with a previously reported frequency of ETX immunoreactivity in sera from people with clinically definite MS (43%) and age-matched controls (16%) (71). This suggests that there is a high translation rate of the C. perfringens type B/D virulence factor, etx, and that the human gastrointestinal tract is a suitable environment for C. perfringens type B/D growth.

We next assessed the relative abundance of etx in fecal microbiota harvested from people with MS and HC. To do this, we performed quantitative analysis of etx abundance relative to universal 16S by TaqMan real-time PCR using a modified 2^–ΔCt method (72). The 2^–ΔCt method allows for normalization of real-time, quantitative PCR data to an internal reference. We assessed the abundance of etx relative to universal 16S rRNA in MS and HC and found that etx abundance was significantly increased in fecal microbiota harvested from people with MS compared with people who were HCs (Figure 2, A and B).

Figure 2

etx abundance and etx-harboring strains increase in the fecal microbiota of patients with MS. (A and B) Representative amplification plots (A) and statistical analysis of etx abundance (B) by TaqMan real-time PCR analysis. Of note, the system detected 15 etx⁺ patients with MS, fewer than what was detected by standard PCR (19). (C–E) cpa abundance in people who were healthy controls (HCs) and patients with MS. (F) Multiplex PCR reveals different composition of strains in the fecal C. perfringens community from participants who were etx⁺. Participants labeled in red are included as known etx^– samples from (1B) and included for comparison. Of note, C. perfringens type E, defined by the presence of cpa and itx, is present in MS3, MS31, and HC1; while MS19, MS26, HC1, and HC4 carry cpb, a virulence determinant carried by C. perfringens types C and B. (G–I) Analysis of the etx/cpa ratio by TaqMan real-time PCR using the C. perfringens type B (ATCC3626) and type D (FD203) strains as a calibrator for the quantification of etx⁺/etx^– strain ratios in the fecal microbiota from etx⁺ participants. Quantification of the ratio of etx/cpa by 2^–ΔCt (G), etx/cpa against type D culture as calibrator by 2^–ΔΔCt (H). Dashed horizontal lines in G and H show 2^–ΔCt/2^–ΔΔCt values from culture of indicated reference strains. Estimate of maximum of percentages of etx^– and etx⁺ strains in etx⁺ HC and MS fecal microbiome (I). The estimates assume that the individuals with a 2^–ΔΔCt value above 1 (type D) contain 100% etx⁺ strains. P value determined by Mann-Whitney test (non-Gaussian distribution). Number of participants (n) is indicated in individual panels; black lines in B–E, and H indicate medians. Data in G are mean ± SD, n = 3 technical triplicates in a representative real-time PCR experiment). Similar results were achieved in 3 independently repeated PCR/qPCR experiments using the same participants.

C. perfringens type A strains, defined by presence of the chromosomally encoded α toxin gene, cpa, but none of the other major toxin genes, are human intestinal commensals (27, 73). C. perfringens type B strains carry the cpa, cpb, and etx toxin genes, whereas C. perfringens type D strains carry the cpa and etx genes (27). Our PCR analysis identified cpa in 74% of patients with MS compared with 45% of people who were HCs (Supplemental Figure 2, A–C). When cpa prevalence was analyzed in subgroups of participants, according to the presence or absence of etx, cpa coexisted with the etx gene in participants who were etx⁺ (Supplemental Figure 2D). Interestingly, cpa prevalence among participants who were etx^– was essentially indistinguishable between people with MS and people who were HCs (Supplemental Figure 2D). These results suggest non-etx strains (cpa⁺, etx^–) are unlikely to be involved in MS. TaqMan real-time PCR showed a significant increase in cpa abundance for people with MS compared with people who were HCs (Figure 2C). No statistical difference for cpa abundance was found among subgroups according to etx presence/absence (Figure 2, D and E). Neither prevalence nor abundance of cpa from participants who were etx^– differed between individuals with MS and people who were HCs, ruling out a role for non-etx strains in MS pathogenesis. However, an increase in cpa prevalence in the MS group (etx^– and etx⁺ combined) compared with the HC group (Figure 2C) suggests that people with MS may have a more suitable gastrointestinal environment for the survival and growth of C. perfringens.

Quantification by TaqMan real-time PCR simultaneously targeting genes encoding C. perfringens–specific 16S rRNA and universal 16S rRNA confirmed an increase of C. perfringens abundance in people with MS compared with people who were healthy controls (Supplemental Figure 3A). Using the 2^–ΔΔCt method (72) with pure reference strains as calibrators, participants with MS trended toward higher percentages of C. perfringens in fecal microbiota when compared with people who were healthy controls, but this did not achieve statistical significance (Supplemental Figure 3, B–D). Of note, our estimates agree with the previously reported range (0.000001%–0.01%) of C. perfringens abundance in fecal microbiota from healthy humans, confirming the organism’s low abundance (66, 74).

The 2018 revised classification scheme for C. perfringens defines 7 distinct toxinotypes based on carrying 1 or more of 6 major toxin genes (plc/cpa, cpb, etx, iap/iab, cpe, and netB) (27). We performed multiplex PCR for the major toxins used to characterize C. perfringens toxinotypes within our etx⁺ HC and MS populations (Figure 2F) (27). The majority of patients with MS who were etx⁺ harbored C. perfringens type D strains (etx⁺, cpa⁺) with fewer type B (etx⁺, cpa⁺, cpb⁺) strains detected (Figure 2F). C. perfringens enterotoxin (cpe), which is the main agent of C. perfringens–mediated human food poisoning, was not detected. Notably, unlike the more sensitive singleplex PCR (Figure 1C), etx and cpa appeared to be absent in some participants by multiplex PCR, likely due to issues of annealing temperature compatibility among individual primer pairs in the multiplex PCR system. The apparent variations of etx/cpa band intensity ratios among participants, which differ from that of reference strains, suggested that some participants likely harbored a community of combined type A strains (cpa⁺) and type B/D strains (cpa⁺, cpb⁺, etx⁺ or cpa⁺, etx⁺).

We next examined the significance of etx-positivity in the individuals who were HCs. Our multiplex PCR result suggested that there was a distinct lack of or weakened etx band in the group of 4 etx⁺ HC participants (Figure 2F), despite etx being clearly detected in singleplex PCR (Figure 1, B and C). To understand this phenomenon, we developed a sensitive TaqMan real-time PCR to simultaneously target etx and cpa genes and used the 2^–ΔΔCt analysis to quantify the relative abundance of etx-producing (cpa⁺, etx⁺) over non-etx–producing strains (cpa⁺, etx^–) from etx⁺ MS and HC groups. The 2^–ΔCt value (Figure 2G) was computed to quantify fold changes of the etx/cpa ratio when a pure type D (cpa⁺, etx⁺) culture was used as a calibrator (Figure 2H). A value of 1 was set as the 2^–ΔΔCt for the type D calibrator. We reasoned that a 2^–ΔΔCt value greater than 1 indicated the dominance of etx-encoding strains with increased etx-plasmid copy numbers, and that a 2^–ΔΔCt value of less than 1 indicated a higher percentage of C. perfringens type A (cpa⁺) in the bacterial community. Our results revealed significantly increased 2^–ΔΔCt values for the etx/cpa ratio in people with MS compared with people who were HCs (Figure 2H).

Since a 2^–ΔΔCt value of at least 1 would suggest that 100% of a participant’s C. perfringens strains were etx-harboring (i.e., type B and/or type D), we then obtained a maximum estimate of the average percentage of etx-harboring strains in the C. perfringens community for people with MS or people who were HCs. Our analysis showed that participants with MS who were etx⁺ had 32% etx-harboring strains and 68% non-etx C. perfringens strains (Figure 2I). In contrast, people who were healthy controls but were etx⁺ had 0.002% etx-harboring strains and nearly 100% non-etx C. perfringens strains. Analysis from a different perspective by quantifying the abundance of etx over C. perfringens-specific 16S rRNA yielded a higher estimate of the percentage of etx-harboring strains; 43% in people with MS and a lower percentage, 0.001%, in people who were healthy controls (Supplemental Figure 4).

Together, these data consistently show that people with MS are more likely to be colonized by etx⁺ strains of C. perfringens in their gut microbiome than are age- and gender-matched people who are HCs. Our data suggest that there is likely a yet-to-be defined threshold of relative abundance of ETX-producing strains, with relative abundance beyond this threshold contributing to MS. The complex dynamic between C. perfringens type A strains and the etx-encoding strains is likely important, since type A strains compete with other C. perfringens strains for resources and because conjugative transfer between etx plasmid-harboring type D and etx-negative type A have been previously demonstrated in vitro (75).

Comparison of patient-derived, laboratory, and environmental isolates. We next sought to determine if patient-derived isolates from people with MS shared features with known environmental isolates and if they produced functional ETX. We conducted whole genome sequencing of an isolate derived from a patient with MS (SHDS0050), several environmental isolates, including type D strains isolated from ruminants, and our laboratory type B strain. We successfully sequenced a closed 54.5 kb plasmid derived from isolate pSHDS0050 (Figure 3A). This plasmid contained 63 ORFs and an etx locus flanked by mobile genetic elements. As with other etx plasmids, pSHDS0050 had a Tn3 (in the opposite orientation) and an IS1151 transposase upstream of etx (76), but had 2 IS256 and a mutator type transposases directly after (Figure 3C). The plasmid resembled other highly conjugative plasmids of the pCW3 family that are found in C. perfringens strains, as it contained the tcp locus and other genes associated with conjugation (77) and the central control region containing the parMRC partitioning system (78). The plasmid lacked other toxin genes such as cpe and cpb. When comparing the type D plasmid derived from a patient with MS to the other etx-containing type B and D plasmids sequenced in this study, pSHDS0050 maintained the same conserved genes such as regB, pemK, amidoligase, permease, RICIN domain containing genes, and a radical SAM gene (Figure 3C). Interestingly, pSHDS0050 had identical plasmid architecture to the sheep isolate NCTC8346 and the goat isolate FU17 (Figure 3C), which suggests that ruminants may be a potential vector for infecting humans, as originally hypothesized by Murrell (79). Although sharing much of the same genomic content, these type D plasmids were neither as large as the 64.7 kb etx plasmids sequenced in this study from the type B strains ATCC3626 and NCTC3110 nor the published type B strain, NCTC8533 (Figure 3C) (80). pSHDS0050 lacked genes such as cpb2, thiF and pri present in those plasmids.

Figure 3

Characterization of patient-derived strain SHDS0050 and its comparison to environmental and laboratory ETX-producing strains. (A) The circular map of etx⁺ plasmid (pSHDS0050) from a MS patient-derived SHDS0050 strain. Hypothetical and proteins of unknown function ORFs are colored black, those involved in conjugation are purple, toxin ORFs are red, DNA methylases are green, transposases and recombinases are gray, ribonucleases are pink, plasmid replication ORFs are blue, conserved etx plasmid ORFs are red, and ABC transporters are magenta. (B) GView BLAST Atlas map comparing the circular chromosomes of pSHDS0050 as the reference genome to etx⁺strains CN3842, FU17, NCTC8346, ATCC3626, and NCTC3110. Type D chromosomes are shades of blue, while type B are shades of red. Colored regions for genomes indicate a BLAST hit present in the reference genome. Empty slots indicate no matching hits. SHDS0050 genome is distinct from other strains. (C) Linearized plasmid map comparisons comparing pSHDS0050 with the etx plasmids of 3 type D collection strains pCN3842, pFU17etx, and pNCTC8346etx, and 2 type B strains pATCC3626etx and pNCTC3110etx. The linearized maps use the same color scheme as A, with different transposase ORFs having different pattern fillings. The 3 type D strains share the same gene content and share many of the same genes. (D) Western blot analysis for pETX production from indicated C. perfringens strains. pETX spiked into PBS or broth were used as positive controls. Broth only was used as a negative control. (E) Susceptibility of hMAL-CHO or GFP-CHO cells to activated ETX. To confirm if cell death was ETX mediated, broth was pretreated with a neutralizing anti-ETX antibody. Broth alone was used as a negative control. Cell death was determined by PI staining. n = 3. ****P < 0.0001 determined by 2-way ANOVA with Šidák’s multiple comparisons test.

We next compared the circularized chromosomes of the type D strains CN3842, NCTC8346, and FU17, and the type B strains ATCC3626 and NCTC3110 to ensure that patient strain SHDS0050 was not a collection strain contamination. A GView BLAST atlas plot revealed that the patient-derived strain had multiple unique regions within its chromosome, distinguishing it from the other isolates (Figure 3B).

To evaluate production of epsilon protoxin (proETX) and pathogenicity, we cultured SHDS0050, the ATCC type B strain, and a ATCC type F strain in TGY broth under anaerobic conditions and assessed supernatants for proETX by Western blot. The strain derived from a patient with MS produced an approximately 32.9 kDa proETX protein of similar mobility to the ATCC type B strain (Figure 3D). The ATCC type F strain was negative for ETX production, as anticipated. To evaluate cytotoxicity, harvested supernatants were treated with trypsin to activate ETX. Next, CHO cells expressing the human ETX receptor, MAL (hMAL-CHO) (54), or control CHO cells expressing GFP (GFP-CHO) were treated with trypsin-activated supernatants. Cell death was determined by propidium iodide (PI) exclusion assay. To confirm that the cytotoxic effects were ETX mediated, trypsin-activated supernatants were also treated with a neutralizing anti-ETX antibody (81) prior to CHO cell treatment. Only the trypsin-activated supernatants from the lab type B and type D strain derived from a patient with MS, SHDS0050, induced hMAL-CHO cell death (Figure 3E). Cell death was not observed in hMAL-CHO cells treated with broth alone, and GFP-CHO cells were insensitive to all treatment conditions (Figure 3E). Anti-ETX antibody treatment inhibited hMAL-CHO cell death, indicating that the supernatant cytotoxicity was ETX mediated. Collectively, these data indicate that our C. perfringens type D strain derived from a patient with MS possessed typical type D plasmid architecture, was competent to produce functional ETX, and conceivably could have arisen from a ruminant source.

SNPs in bacterial genes have been linked to microbial fitness (82) and the ability of pathogens to cause disease (83). Large-scale genomic analyses have identified abundant SNPs in the C. perfringens genome (84, 85). To characterize these variants, we collated 17 etx genes with coding DNA sequences (CDS) available through the National Center for Biotechnology Information (NCBI) database and performed a comparative alignment analysis. The SNP at site 762 carried the least conserved SNP among the 6 that we identified and was the only SNP present in the coding sequence of activated ETX. The minor allele at the 762 site was a substitution of guanine for adenine (762G), regardless of C. perfringens toxinotype (Supplemental Figure 5C).

The etx genes isolated from the human fecal samples in our study predominantly (95%, 20 of 21) carried the minor allele at site 762, 762G (Supplemental Figure 5D). This variant resulted in a synonymous mutation at residue 254, where Serine corresponded to residue 222 in activated ETX, in the receptor binding domain (49). Emerging evidence indicates that synonymous mutations, previously assumed to be phenotypically neutral, contribute to microbial fitness. Furthermore, synonymous mutations can affect mRNA secondary structure, protein translation, and protein folding (86).

ETX overcomes CNS immune privilege. Circulating myelin-autoreactive lymphocytes are common in the general population (87). Despite the prevalence of myelin autoreactive lymphocytes among humans, widespread autoimmunity is minimized by mechanisms of peripheral tolerance and CNS barriers to preserve immune privilege (88–90). The importance of CNS barriers in maintaining immune privilege is well demonstrated in active immunization models of EAE. In this model system, animals are immunized with a myelin antigen, typically a myelin-specific protein or peptide, in complete Freund’s adjuvant (CFA) (91). In most paradigms, immunized animals do not develop clinical or histologic CNS disease unless they also receive PTX, which targets CNS endothelial cells at the BBB (91–93). Similarly, in many myelin peptide-specific T cell receptor (TCR) transgenic models, EAE occurs infrequently unless animals receive PTX, despite the TCR repertoire being biased toward unusually high frequencies of autoreactive clones (91, 94). Although PTX is extensively used in EAE to overcome immune privilege, it is clinically irrelevant to MS.

Knowing that bloodborne ETX specifically targets CNS endothelial cells (26), we wanted to test if ETX was sufficient to breach CNS immune privilege in the presence of circulating myelin autoreactive lymphocytes. We adapted a widely used immunization model of EAE using the immunodominant peptide in the myelin oligodendrocyte glycoprotein (MOG) (91). On day 0, female C57BL/6 mice received an s.c. injection of 200 μg of synthesized mouse MOG_35-55, emulsified in 50 μl of CFA. On days 0 and 2, mice received either PTX at 5 μg/kg body weight (approximately 100 ng per mouse), ETX at 50 ng/kg body weight (approximately 1 ng per mouse), or ETX at 500 ng/kg body weight (approximately 10 ng per mouse), all delivered i.p.

ETX, like PTX, was sufficient to induce clinical disease in mice immunized with MOG peptide 35–55 (MOG_35-55) (Figure 4A). In the absence of either toxin, MOG_35-55–immunized animals remained healthy and without an observable phenotype. Disease activity induced by ETX occurred at doses significantly lower than that of PTX (50 ng/kg or 500 ng/kg for ETX, and 5 μg/kg for PTX). Onset, temporal course, and peak clinical deficits were similar for ETX- and PTX-induced EAE when using the classical EAE scoring scale (Figure 4A). The magnitude of demyelination in the spinal cord and the ultrastructural characteristics of demyelination were similar comparing ETX-induced EAE (ETX-EAE) with PTX-induced EAE (PTX-EAE, Figure 4, B and C). These results indicate that ETX is a potent inducer of EAE in the context of a MOG_35-55/CFA immunization paradigm.

Figure 4

Comparison of ETX- and PTX-EAE in the spinal cord using the classical scoring scale. (A) Classical EAE time-course (left panel) of mice from indicated experimental groups. Mice immunized with CFA/PBS (PBS) or CFA/MOG_35-55 (MOG) were injected i.p. with PTX at 5 μg/kg, ETX at 50 ng/kg (ETX-Lo), or ETX at 500 ng/kg body weight (ETX-Hi) on days 0 and 2 following immunization. Quantification of day of disease onset, peak EAE score, and increasing EAE score (right panels). (B) Representative sections of lumbar spinal cord from mice sacrificed at day 30 stained with Luxol Fast Blue (myelin stains blue). Red circles and black arrowheads indicate demyelination in the dorsal column (dc) or in the lateral and ventral funiculi, respectively. Dashed pink lines indicate lesion border in ventral white matter (WM) tracts. Quantification of myelin integrity (%, middle panel) generated from binary images (right panel). (C) Electron microscopy (left panel) and quantification (middle and right panels) evaluating demyelination in ETX-EAE mice. Red asterisks indicate demyelinated axons; yellow rectangles highlight ultrastructural changes of myelin sheath; cyan arrowhead indicate decompacted myelin sheath; yellow arrowheads indicate splitting myelin sheath and debris; red arrow indicates expanded space between an axon and myelin. Data in left panel of A are mean ± SEM; data in right panels of A and B represent median ± range; Kruscal-Wallis test (nonparametric); NS, not significant; n = 4 mice for PBS > PTX and PBS > ETX-Hi controls, n = 6 mice for MOG > EAE-Lo, and n = 8 mice groups MOG > PTX and MOG > ETX-Hi. Data in C represent mean ± SD; unpaired t test; *** P < 0.001; n = 24 fields from 2 mice. Scale bars: 1 mm (B), 500 nm (C, top panels), and 200 nm (C, lower panels). Similar results for 2 independent experiments.

ETX-EAE induces multi-focal demyelination. ETX-EAE groups displayed a wider array of behavioral deficits when compared with PTX-EAE, including ataxia, head tilt, imbalance, axial rotation, and left/right leaning, as captured by the atypical EAE scoring scale (Figure 5A and Supplemental Figure 6). Demyelination in PTX-EAE mice was largely restricted to the spinal cord (Figures 4 and 5). In contrast, ETX-EAE mice developed multifocal demyelination more typical of MS (Figure 5B). Compared with PTX-EAE, ETX-EAE mice had nearly twice as many lesions in the cerebellum, and lesions in the corpus callosum were only observed in the ETX-EAE group (Figure 5C). ETX-induced EAE showed perivenular cuffs of mononuclear cells and mononuclear infiltrates that correlated with demyelination (Supplemental Figure 7).

Figure 5

ETX-EAE is characterized by multifocal demyelination in the CNS. (A) ETX-EAE mice developed atypical EAE, which is characterized by ataxia, along with classical EAE symptoms defined by ascending paralysis. Same treatment conditions as in Figure 4, CFA/MOG_35-55 followed by ETX (ETX-EAE) or PTX (PTX-EAE). (B) ETX targets broader brain regions compared with PTX including cerebellum (Ceb) and corpus callosum (cc). ETX-EAE mice (left column) exhibit more focal demyelinating lesions (arrowheads and red dashed circles) in the cerebellum and corpus callosum within WM tracts when compared with PTX-EAE mice (right column). Asterisk in lower row indicates demyelinated cc. Black arrows indicate borders of a cc lesion, which is also framed with a red dashed rectangle. A corresponding location in PTX- EAE mice (right column) is indicated by white arrows. Regions framed with black boxes are shown at high magnification in inserts. (C) Quantification of lesions in the cerebellum and corpus collosum. Data in A are mean ± SEM, and data in C represent median ± range; Kruscal-Wallis test (nonparametric). n = 4 mice for PBS > PTX and PBS > ETX-Hi controls, n = 6 mice for MOG > ETX-Lo, and n = 8 mice for groups including MOG > PTX and MOG > ETX-Hi. NS, not significant. Scale bars: 1 mm in B and 100 μm in the inserts. Similar results were achieved in 2 independently repeated experiments.

We next wanted to compare the immune infiltrates in brain and spinal cord between the ETX- and PTX-EAE models. We examined histologic sections in ETX-EAE, PTX-EAE, and controls for infiltrating CD4⁺ lymphocytes. While both models induced similar demyelination in the spinal cord, PTX-EAE showed significantly more infiltrating CD4⁺ T cells in the spinal cord compared with ETX (Figure 6, A and E). For the cerebellum, there were significantly more infiltrating CD4⁺ lymphocytes and more CD4⁺ lymphocytes in perivascular cuffs in the ETX-EAE model compared with PTX-EAE (Figure 6, B–F). In the thalamus, there was a similar trend toward more peri-venular CD4⁺ T cell infiltrates in ETX-EAE when compared with PTX-EAE (Figure 6, C–F). In the spinal cord, similar activation of inflammatory processes was observed in both models at peak disease, based on immunohistochemical analysis of phospho-NFκB p65, CD68, and CD45 (Figure 7 and Supplemental Figure 8). In the cerebellum, however, CD68 was significantly increased in ETX-EAE but not PTX-EAE mice (Figure 7, A–C). A similar trend was also observed in the cerebellum for phospho-NFκB p65 and CD45, but this did not achieve statistical significance (Figure 7, A–E and Supplemental Figure 8). These results, collectively with data from Figures 4 and 5, indicate that ETX induced multifocal, inflammatory demyelination in a neuroanatomic distribution more consistent with MS and with a stronger correlation between immune infiltrates and demyelination in the ETX-EAE model compared with PTX-EAE (Supplemental Figure 9).

Figure 6

ETX-EAE mice show increased CD4⁺ lymphocyte infiltration in the cerebellum and thalamus compared with PTX-EAE. Sections from mice sacrificed at day 30 after immunization with CFA/MOG_35-55 followed by ETX (ETX-EAE) or PTX (PTX-EAE) injection were immunostained with anti-CD4 antibody (brown) and counter-stained with hematoxylin (purple). (A–C) Representative CD4 staining in spinal cord (A), cerebellum (B) and thalamus (C). In ETX-EAE mice, CD4⁺ cells were found in perivascular cuffs and surrounding parenchyma indicated by arrowheads and shown in boxed regions of B and C. CD4⁺ cells from PTX-EAE mice were localized to perivascular space or scattered (arrowhead and arrow). Boxed regions shown at higher magnifications to illustrate morphological details. A high magnification micrograph (bottom panel in B) depicts CD4⁺ staining (black arrow). OT, optic tracts; ML, medial lemniscus; PC, posterior commissure. (D) ImageJ-generated binary drawings on CD4⁺ distribution in the white matter (WM) of a PTX-EAE spinal cord (SC, orange arrows) and ETX-EAE cerebellum (Ceb). In Ceb, orange arrowheads indicate CD4⁺ cells confined to a single layer in the meninges (upper boxed region). Perivascular localization of CD4⁺ cells shown at a higher magnification in the cerebellum of ETX-EAE mice (lower boxed region). GM, gray matter. Scale bars: 1 mm (top row A, and left column B), 2 mm (top and third rows in left column in C), 200 μm (high magnification of boxed regions A–C), 500 μm (D, left column), 100 μm (D, right column), and 50 μm (B, bottom right panel). (E and F) Quantification of number of CD4⁺ cells (E) and CD4⁺ perivascular cuffs (F) in indicated CNS regions. Data represent median ± range; Kruscal-Wallis test (nonparametric). NS, not significant. n = 4 and 8 mice for controls (PBS > PTX; PBS > ETX-Hi) and EAE groups (MOG > PTX; MOG > ETX-Hi), respectively. Similar results were obtained from 2 independent experiments.

Figure 7

ETX-EAE mice show increased CD68⁺ microglia in the cerebellum of ETX-EAE mice compared with PTX-EAE mice, despite similar activation in the spinal cord and a comparable profile of transcription factor NFκB p65 in both models. (A) Representative sections from mice sacrificed at day 30 after immunization with CFA/MOG_35-55 and followed by either ETX (ETX-EAE) or PTX (PTX-EAE) injections were immunostained with anti-CD68 antibody or anti-phospho-NFκB p65 (Ser 276). A rectangle-framed region in each condition in A is shown at a higher magnification beneath the corresponding section. SC, spinal cord; Ceb, cerebellum. Note that adjacent sections in each group were used for staining against CD68 and phospho-NFκB p65. Scale bars: 500 μm (bottom, spinal cord); 50 μm (top, spinal cord); 1 mm (bottom, cerebellum); 20 μm (top, cerebellum). (B–E) Statistical analysis of staining intensity for CD68 (A and B) and phosphor-NFκB p65 (pNFκB; D and E) in the spinal cord (B and D) and cerebellum (C and E), respectively. Data represent median range; Kruscal-Wallis test (nonparametric). NS, not significant. n = 4 and 8 mice for controls (Control: PBS > PTX; ETX: PBS > ETX-Hi) and EAE groups (PTX-EAE: MOG > PTX; ETX-EAE: MOG > ETX-Hi), respectively.

Human lymphocytes, but not mouse lymphocytes, express the ETX receptor, MAL (54, 58, 95). While it seemed unlikely that ETX functions to induce active EAE by affecting peripheral immunity, we nevertheless wanted to test this possibility through tracking MOG_35-55–specific T cell cytokine responses via antigen recall experiments. To track the fate of MOG_35-55–specific T cell responses in vivo (96–98), we transferred naive, purified MOG_35-55–specific CD4⁺ T cells from MOG_35-55–specific TCR transgenic (2D2) mice into recipient WT B6 mice 24 hours before induction of active EAE by s.c. immunization with MOG_35-55 in CFA. Immunized mice then received either PBS, 10 μg/kg PTX, or 500 ng/kg ETX immediately after immunization and again 48 hours later (Supplemental Figure 10A). We monitored mice for the onset of clinical disease (Supplemental Figure 10B), and, 14 days following immunization, we generated single-cell suspensions from inguinal lymph nodes, cervical lymph nodes, and from the CNS (brain and spinal cord) and processed these for either direct analysis of basal cytokine production by flow cytometry (Supplemental Figure 10C) or for cytokine production after antigen recall via ex vivo restimulation with MOG_35-55 for 72 hours (Supplemental Figure 10D). For both sets of experiments we assessed intracellular cytokine production by flow cytometry. MOG_35-55–specific 2D2 were positively defined as CD45⁺, CD3/5⁺, CD4⁺, and Thy1.1⁺. Frequencies of TNF-α, IFNγ, or GM-CSF positive CD4⁺ T cells did not significantly differ between PBS controls and ETX-treatment in cervical or inguinal lymph nodes, except for a small difference in the frequency of TNF-α⁺ T cells from inguinal lymph nodes, following 72 hours of restimulation with MOG_35-55 (Supplemental Figure 10D). In CNS tissue, there were no differences noted in the frequencies of TNF-α, IFNγ, or GM-CSF positive CD4⁺ T cells between the ETX and PTX treatment groups. These results support the conclusion that ETX was not functioning through significant effects on peripheral immunity and did not affect MOG_35-55–specific T cell responses during the induction of active EAE.

ETX and PTX alter the CNS endothelial cell transcriptome to induce genes involved in BBB dysfunction. To gain insight into the functional mechanisms of ETX and PTX in overcoming immune privilege at the CNS endothelial barrier, we conducted bulk RNA-Seq on CNS endothelial cells isolated from animals treated with ETX, PTX, or PBS and compared transcriptional profiles.

Mice were treated with PBS, ETX (500 ng/kg BW), or PTX (5 μg/kg BW) on 2 consecutive days followed by isolation of CNS endothelial cells from spinal cord for bulk RNA-Seq. CNS endothelial cells were isolated from spinal cords, as previously described (99), 16 hours after the second toxin dose. Bulk RNA-Seq was performed and analyzed using the limma-voom workflow (100). Principal-component (PC)analysis (Figure 8A) revealed separation by treatment. PC1 distinguished control from both ETX and PTX, whereas PC2 distinguished ETX from PTX, indicating that the ETX and PTX transcriptomes are more like each other than PBS controls. We identified 798 differentially expressed genes (DEGs) between ETX and PBS treated samples, and 905 DEGs between PTX- and PBS-treated samples (FDR q < 0.10). Of these DEGs, 595 changed in response to both ETX and PTX treatments (Figure 8B). Comparing the fold changes (FCs) of the overlapping genes revealed a remarkable consistency in direction and magnitude of differential expression between ETX and PTX treatments (Figure 8C). Considering that PTX is an A-B toxin that functions through ADP-ribosylation of G-proteins and that ETX is a pore-forming toxin of the aerolysin family, the consistency in induced and suppressed genes was both intriguing and unexpected. A heat map displaying genes of interest revealed induction of protease, signal transduction, cytokine, and transcription factor genes potentially relevant to overcoming CNS immune privilege (Figure 8D). In Figure 8E, we show a heat map of genes differentially expressed by ETX and PTX that also were identified by Munji et al. as components of a core set of genes involved in BBB dysfunction (101). The overall gene induction in endothelial cells isolated form PTX- or ETX-treated mice shares a great degree of overlap (Figure 8F). Further analysis with of the RNA-Seq data identified signaling pathways preferentially activated by ETX (Figure 8G).

Figure 8

Transcriptome analysis of ETX- and PTX-treated CNS endothelial cells from spinal cord. (A) Principal-component (PC) analysis of RNA-Seq data, based on the top 1,000 most variable genes. Each symbol represents a biological replicate, and each component is indicated with the amount of variation that it explains. n = 3 mice for PTX and ETX treatment and n = 2 mice for PBS treatment. (B) Venn diagram showing extent of overlap between genes differentially expressed in ETX- or PTX-treated samples relative to control (PBS). (C) Correlation analysis of log₂ fold-changes between genes that change in both ETX and PTX displayed as a scatterplot, R² = 0.96. (D) Heat map of DEGs of interest relevant to immune privilege (FDR < 0.10) in ETX or PTX. (E) Heat map of DEGs induced by ETX and/or PTX reported by Munji (101) in a BBB dysfunction module. (F) Heat map of all DEGs induced by ETX and/or PTX relative to PBS control. (G) Selected pathways predicted to be activated in ETX treated cells by Ingenuity Pathway Analysis (P < 0.05 and z score ≥ 1) based on the differentially expressed genes compared with control cells.

Discussion

We presume the factors responsible for the formation of the initial lesions in MS are the same factors responsible for new lesion formation throughout the course of the disease. That is, environmental triggers for MS likely do not occur all at once at disease initiation, but rather, arise repeatedly throughout the course of disease. The episodic nature of MS disease activity aligns well with the ETX hypothesis. ETX production occurs when C. perfringens types B or D enter log-phase growth and, thus, is tied to increased abundance of these strains in the gut microbiome (28, 50). Brief cycles of log-phase growth followed by long periods of quiescence would account for episodic ETX production. MS disease activity is linked to an increased relative abundance of Bacillota (Firmicutes), which includes the genus Clostridium, suggesting that the MS gut microbiome episodically favors growth of this phylum (11). In addition to our findings, it is notable that the species C. perfringens is the most highly associated bacteria with neuromyelitis optica, which is an immune-mediated, demyelinating disorder affecting the spinal cord and optic nerve (102, 103).

C. perfringens type D is responsible for enterotoxemia in sheep, goats, and, less frequently, in cattle (104). The disease has worldwide distribution and can be acute, sub-acute, chronic, or fatal (105, 106). Although enterotoxemia type D is an infectious disease that can occur in the form of small outbreaks via the oral-fecal route, it is not typically a contagious disease. A variable number of ruminants harbor C. perfringens type D in their small intestine, but microorganism numbers are generally small and clinical disease does not occur unless the intestinal microbial balance is disrupted (106, 107). When large quantities of readily fermentable carbohydrates are fed to these animals, undigested starch passes into the small intestine and provides a substrate for C. perfringens to proliferate rapidly. This is followed by production of large amounts of ETX, which is then absorbed into the systemic circulation. The bacteria are passed by feces into the environment and can survive for several months in the soil. Neonates and older animals become infected via the fecal-oral route.

The Epstein Barr Virus (EBV) has been proposed as an environmental trigger for MS (108), potentially functioning through molecular mimicry (109). In humans, EBV is significantly associated with MS, but seroconversion is itself not sufficient to induce MS; approximately 94% of the general population is seropositive by age 24, yet MS risk remains relatively low (108, 110, 111). This suggests that, while EBV may play a role in MS pathogenesis, an additional, but less widely distributed causal factor, as discussed by Carl Nathan (112), is required, which we propose to be C. perfringens type B or D.

In summary, we found a strong clinical association between a specific bacterium, its toxin, and a diagnosis of MS. In addition, we found that the abundance of ETX-producing strains of C. perfringens was significantly elevated in the gut microbiome of patients with MS. We provided a biologically plausible mechanism by which ETX functions in the multistep process of CNS autoimmunity. Ultimate proof of this hypothesis, as would be the case for any environmental factor, will require a clinical trial to neutralize ETX or to eliminate C. perfringens type B or D in the human host.

Methods

Details on participant recruitment, reagents, and experimental methods are found in supplemental materials.

Data and materials availability. C. perfringens chromosome and plasmid sequences were deposited into GenBank under the following accession numbers (chromosome, plasmid for each strain): C. perfringens type D CN3842 (CP116428, CP116429), C. perfringens type D NCTC8346 (CP116430, CP116431), C. perfringens type D FU17 (CP116432, CP116433), C. perfringens type D SHDS0050 (CP116434, CP116435), C. perfringens type B NCTC3110 (CP116436, CP116437), and C. perfringens type B ATCC3626 (CP116438, CP116439).

Statistics. Statistical analysis was performed using GraphPad Prism (v.9; GraphPad) and Microsoft Excel (2016; Microsoft). Data of Gaussian distribution are represented as mean ± SEM or SD, as indicated. Data of non-Gaussian distribution are represented as median ± range. Unpaired 2-tailed t test (for Gaussian distribution) or Mann–Whitney test (for non-Gaussian distribution) were used to compare 2 data sets for statistical significance. For multiple data sets, 1-way ANOVA followed by post hoc Tukey’s multiple comparisons test (for Gaussian distribution), Kruskal–Wallis test followed by post hoc Dunn’s multiple comparisons test (for non-Gaussian distribution), or 2-way ANOVA with Šidák’s multiple comparisons test were carried out to determine statistical significance as indicated. For EAE time course analysis, nonparametric Friedman’s test followed by post hoc Dunn’s test was performed. Pearson’s correlation analysis was performed to examine whether the density of CNS infiltrating lymphocytes correlated with the extent of demyelination. One phase decay model was employed for curve fitting. Multivariable logistic regression was used to test the difference while adjusting for covariates. P values are stated in figures and legends.

The RNA-Seq data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (113) and are accessible through GEO Series accession number GSE223137.

Study approval. The HITMS Study, protocol # 1003010940, was approved by the Weill Cornell Medicine Institutional Review Board. All study participants received, reviewed, and signed a written informed consent.

The Weill Cornell Medicine IACUC approved all experimental procedures with animals, which were also consistent with the ethical guidelines of the NIH.

Author contributions

YM conceptualized, designed, and carried out EAE experiments and performed histological and ultrastructural analyses. He conceptualized quantification methods and carried out the analyses of fecal samples by standard and TaqMan real-time PCR. He also wrote the IACUC protocol and edited the manuscript. DS conceptualized, designed, and carried out the purification of bacteria from fecal samples using the Nycodenz method, performed the genomic assembly of the human C. perfringens isolates, and created the plasmid maps for the patient and environmental isolates, as well as having edited the manuscript. JRL generated the antibodies used in the detection of ETX and assisted with the design of the study and analysis of etx detection in fecal samples from MS and HC study participants. She also assisted with obtaining the MS participant isolate, conducted the analysis of CHO cell cytotoxicity, isolated endothelial cells and purified RNA from mice used in the analysis of differential gene expression, assisted with writing the IRB and IACUC protocols, and edited the manuscript. SH assisted in the analysis of fecal samples and purification of isolates. BZ performed standard and TaqMan real-time PCR analyses of fecal samples, and assisted with daily monitoring and scoring of EAE mice in all experiments involving the model. JBG designed, conducted, and analyzed the EAE antigen recall and flow cytometry experiments. PZ conducted the analysis of endothelial cell differential gene expression, and constructed the principal component analysis plot, gene ontogeny plot, and heat maps for endothelial cell differential gene expression. FD assisted in the design, analysis, and strategy for endothelial cell differential gene expression. DB performed Ilumina shotgun sequencing and Nanopore long reads on purified bacterial isolates and edited the manuscript. CPP advised and assisted with CNS endothelial cell isolation and preparation of RNA for bulk RNA seq experiments. KT edited the manuscript. PNW performed Western blot analysis on supernatants from clinical isolates. KRR assisted with design of the study, interpretation of data, and edited the manuscript. SAG assisted with design of the study, developed the RedCap database for entering secure demographic and clinical information on recruited subjects, and edited the manuscript. VAF assisted with the design of the study, interpretation of results, and edited the manuscript. BAM assisted with the analysis and interpretation of the plasmid maps for patient derived strains and environmental strains and edited the manuscript. FAU provided the C. perfringens types B and D environmental isolates., provided background on C. perfringens type D in ruminants, and edited the manuscript. LZ recruited patients for the study and maintained the database. MM assisted with Western blot experiments and figure preparation. RR edited the manuscript. EB edited the manuscript and assisted with antigen recall experiments. DD assisted with plasmid assemblies. JP recruited patients for the study. UK recruited patients for the study. NN recruited patients for the study. ILB edited the manuscript. ZC reviewed the power calculation for the analysis of etx in human fecal samples, multivariable logistic regression, and reviewed all statistical methods. JZX assisted with RNAseq strategy, RNA quality check, library generation, and sequencing. DB supervised and designed the bioinformatics approach for endothelial cell differential gene expression. RD assisted with design of the transcriptional profiling experiments and interpretation of the RNA-Seq data sets and designed the strategy for isolation of CNS endothelial cells from whole animals for bulk RNA-seq. GFS conceptualized, supervised, and interpreted the EAE experiments. CEM designed the sequencing strategy for C. perfringens strains. TV conceptualized and supervised the overall study, conceptualized and designed the analysis of fecal samples for etx detection, conceptualized the EAE experiments, conceptualized and designed the CNS endothelial cell RNA-Seq experiments, analyzed and interpreted data from the etx detection, EAE, and CNS endothelial cell RNA-Seq experiments. They were also responsible for writing and adhering to the IRB and IACUC protocols, and wrote the manuscript. The order of the co–first authors was based on the time and effort devoted to this project.

Acknowledgments

We received technical assistance from Fengxia Liang, Chris Petzold, and Kristen Dancel-Manning at the Electron Microscopy Core of New York University (New York City, New York, USA) for ultrastructural analysis. We thank the Weill Cornell Genomics Core for sequencing the Illumina samples on their NovaSeq S4 and assisting with demultiplexing. We thank Regina Alice Schroeder, Samantha Shetty, Mason Kruse-Hoyer, Melanie Marcille, and Nicole Zinger for their help in recruiting study participants. Most importantly, we are grateful to all the people with MS who volunteered to participate in the HITMS study. Illustrations were made in BioRender. This work was supported by National Multiple Sclerosis Society Research Grant RG4965A4 (TV), National Institutes of Health grant R21 RNS106581A (TV), National Institutes of Health grant R01AI162936 (GFS), National Multiple Sclerosis Society Career Transition Award TA-1604-08444 (JRL), National Institutes of Health Medical Scientist Training Program grant (T32GM007739) to the Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program (EB), National Institutes of Health grants R01AI151059 and R01MH117406 (CEM), and generous gifts from the Diane Kemper Goldman Trust, and the Wilma S and Laurence A Tisch Foundation.

Address correspondence to: Timothy Vartanian or Christopher Mason, Weill Cornell Medical College, Cornell University, 1305 York Avenue, New York, New York 10021, USA. Email: tiv2002@med.cornell.edu (TV); Email: chm2042@med.cornell.edu (CM).

Footnotes

Conflict of interest: YM, JRL, KRR, VAF, and TV are inventors on a patent application (US Patent No: US 9,758,573 B2 ) for a method to diagnose and treat multiple sclerosis using anti-ETX monoclonal antibodies. RR, YM, JRL, KRR, VAF, and TV own equity in Astoria Biologica.

Reference information: J Clin Invest. 2023;133(9):e163239.https://doi.org/10.1172/JCI163239.

References

Dawson J. The histology of disseminated sclerosis. Trans Roy Soc Edin. 1916;50:517–740.
View this article via: CrossRef PubMed Google Scholar

Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Perspect Med. 2018;8(3):a028936.
View this article via: CrossRef PubMed Google Scholar

Absinta M, et al. Direct MRI detection of impending plaque development in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2015;2(5):e145.
View this article via: CrossRef PubMed Google Scholar

Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol. 2004;55(4):458–468.
View this article via: CrossRef PubMed Google Scholar

Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol. 2004;3(12):709–718.
View this article via: CrossRef PubMed Google Scholar

Thompson AJ, et al. Multiple sclerosis. Lancet. 2018;391(10130):1622–1636.
View this article via: CrossRef Google Scholar

Miyauchi E, et al. The impact of the gut microbiome on extra-intestinal autoimmune diseases. Nat Rev Immunol. 2022;23(1):9–23.
View this article via: PubMed Google Scholar

Jangi S, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016;7:12015.
View this article via: CrossRef PubMed Google Scholar

Berer K, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A. 2017;114(40):10719–10724.
View this article via: CrossRef PubMed Google Scholar

Chen J, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6:28484.
View this article via: CrossRef PubMed Google Scholar

Cosorich I, et al. High frequency of intestinal T_H17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Sci Adv. 2017;3(7):e1700492.
View this article via: CrossRef PubMed Google Scholar

Cekanaviciute E, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A. 2017;114(40):10713–10718.
View this article via: CrossRef Google Scholar

Ventura RE, et al. Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course. Sci Rep. 2019;9(1):16396.
View this article via: CrossRef PubMed Google Scholar

Mirza A, et al. The multiple sclerosis gut microbiota: a systematic review. Mult Scler Relat Disord. 2020;37:101427.
View this article via: CrossRef Google Scholar

Cantoni C, et al. Alterations of host-gut microbiome interactions in multiple sclerosis. EBioMedicine. 2022;76:103798.
View this article via: CrossRef Google Scholar

Ghezzi L, et al. Targeting the gut to treat multiple sclerosis. J Clin Invest. 2021;131(13):e143774.
View this article via: JCI CrossRef PubMed Google Scholar

Miyake S, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters. PLoS One. 2015;10(9):e0137429.
View this article via: CrossRef PubMed Google Scholar

Mirza AI, et al. The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. Mult Scler Relat Disord. 2022;63:103829.
View this article via: CrossRef PubMed Google Scholar

iMSMS Consortium. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell. 2022;185(19):3467–3486.
View this article via: CrossRef PubMed Google Scholar

Wekerle H. Nature, nurture, and microbes: The development of multiple sclerosis. Acta Neurol Scand. 2017;136 Suppl 201:22–25.
View this article via: CrossRef PubMed Google Scholar

Rothhammer V, et al. Microglial control of astrocytes in response to microbial metabolites. Nature. 2018;557(7707):724–728.
View this article via: CrossRef PubMed Google Scholar

Rothhammer V, et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med. 2016;22(6):586–597.
View this article via: CrossRef PubMed Google Scholar

Miyauchi E, et al. Gut microorganisms act together to exacerbate inflammation in spinal cords. Nature. 2020;585(7823):102–106.
View this article via: CrossRef PubMed Google Scholar

Schnell A, et al. Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunity. Cell. 2021;184(26):6281–6298.
View this article via: CrossRef PubMed Google Scholar

Sanmarco LM, et al. Gut-licensed IFNgamma(+) NK cells drive LAMP1(+)TRAIL(+) anti-inflammatory astrocytes. Nature. 2021;590(7846):473–479.
View this article via: CrossRef PubMed Google Scholar

Linden JR, et al. Clostridium perfringens epsilon toxin induces blood brain barrier permeability via caveolae-dependent transcytosis and requires expression of MAL. PLoS Pathog. 2019;15(11):e1008014.
View this article via: CrossRef PubMed Google Scholar

Rood JI, et al. Expansion of the Clostridium perfringens toxin-based typing scheme. Anaerobe. 2018;53:5–10.
View this article via: CrossRef PubMed Google Scholar

Chen J, et al. Host cell-induced signaling causes Clostridium perfringens to upregulate production of toxins important for intestinal infections. Gut Microbes. 2014;5(1):96–107.
View this article via: CrossRef PubMed Google Scholar

Chen J, McClane BA. Role of the Agr-like quorum-sensing system in regulating toxin production by Clostridium perfringens type B strains CN1793 and CN1795. Infect Immun. 2012;80(9):3008–3017.
View this article via: CrossRef PubMed Google Scholar

Sayeed S, et al. Epsilon-toxin is required for most Clostridium perfringens type D vegetative culture supernatants to cause lethality in the mouse intravenous injection model. Infect Immun. 2005;73(11):7413–7421.
View this article via: CrossRef PubMed Google Scholar

Goldstein MR, et al. Detection and characterization of Clostridium perfringens in the feces of healthy and diarrheic dogs. Can J Vet Res. 2012;76(3):161–165.
View this article via: PubMed Google Scholar

Regan SB, et al. Identification of epsilon toxin-producing Clostridium perfringens strains in American retail food. Anaerobe. 2018;54:124–127.
View this article via: CrossRef PubMed Google Scholar

Anwar Z, et al. Enrichment and detection of clostridium perfringens toxinotypes in retail food samples. J Vis Exp. 2019;(152).
View this article via: PubMed Google Scholar

Lee CA, Labbe R. Distribution of enterotoxin- and epsilon-positive clostridium perfringens spores in U.S. Retail spices. J Food Prot. 2018;81(3):394–399.
View this article via: CrossRef Google Scholar

Madden RH, et al. Clostridium perfringens as an indicator of hygienic quality of depurated shellfish. J Food Prot. 1986;49(1):33–36.
View this article via: CrossRef PubMed Google Scholar

Davies CM, et al. Survival of fecal microorganisms in marine and freshwater sediments. Appl Environ Microbiol. 1995;61(5):1888–1896.
View this article via: CrossRef PubMed Google Scholar

Miller WA, et al. Salmonella spp., Vibrio spp., Clostridium perfringens, and Plesiomonas shigelloides in marine and freshwater invertebrates from coastal California ecosystems. Microb Ecol. 2006;52(2):198–206.
View this article via: CrossRef PubMed Google Scholar

Skanavis C, Yanko WA. Clostridium perfringens as a potential indicator for the presence of sewage solids in marine sediments. Mar Pollut Bull. 2001;42(1):31–35.
View this article via: CrossRef PubMed Google Scholar

Wade TJ, et al. Rapidly measured indicators of recreational water quality and swimming-associated illness at marine beaches: a prospective cohort study. Environ Health. 2010;9:66.
View this article via: CrossRef PubMed Google Scholar

Li J, et al. Prevalence of enterotoxigenic Clostridium perfringens Isolates in Pittsburgh (Pennsylvania) area soils and home kitchens. Appl Environ Microbiol. 2007;73(22):7218–7224.
View this article via: CrossRef PubMed Google Scholar

Drean P, et al. Characterization of the spore-forming Bacillus cereus sensu lato group and Clostridium perfringens bacteria isolated from the Australian dairy farm environment. BMC Microbiol. 2015;15:38.
View this article via: CrossRef PubMed Google Scholar

Strong DH, et al. Incidence of Clostridium perfringens in American foods. Appl Microbiol. 1963;11(1):42–44.
View this article via: CrossRef PubMed Google Scholar

Wen Q, McClane BA. Detection of enterotoxigenic Clostridium perfringens type A isolates in American retail foods. Appl Environ Microbiol. 2004;70(5):2685–2691.
View this article via: CrossRef PubMed Google Scholar

Talukdar PK, et al. Inactivation strategies for clostridium perfringens spores and vegetative cells. Appl Environ Microbiol. 2017;83(1):e02731-16.
View this article via: PubMed Google Scholar

Talukdar PK, et al. Updates on the sporulation process in Clostridium species. Res Microbiol. 2015;166(4):225–235.
View this article via: CrossRef PubMed Google Scholar

Hatheway CL. Toxigenic clostridia. Clin Microbiol Rev. 1990;3(1):66–98.
View this article via: CrossRef Google Scholar

Hildebrand F, et al. Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. Genome Biol. 2013;14(1):R4.
View this article via: CrossRef PubMed Google Scholar

Bokori-Brown M, et al. Molecular basis of toxicity of Clostridium perfringens epsilon toxin. FEBS J. 2011;278(23):4589–4601.
View this article via: CrossRef PubMed Google Scholar

Savva CG, et al. The pore structure of Clostridium perfringens epsilon toxin. Nat Commun. 2019;10(1):2641.
View this article via: CrossRef PubMed Google Scholar

Popoff MR. Epsilon toxin: a fascinating pore-forming toxin. FEBS J. 2011;278(23):4602–4615.
View this article via: CrossRef PubMed Google Scholar

Freedman JC, et al. Proteolytic processing and activation of Clostridium perfringens epsilon toxin by caprine small intestinal contents. mBio. 2014;5(5):e01994–e01914.
View this article via: PubMed Google Scholar

Harkness JM, et al. Identification of a lambda toxin-negative Clostridium perfringens strain that processes and activates epsilon prototoxin intracellularly. Anaerobe. 2012;18(5):546–552.
View this article via: CrossRef PubMed Google Scholar

Goldstein J, et al. Clostridium perfringens epsilon toxin increases the small intestinal permeability in mice and rats. PLoS One. 2009;4(9):e7065.
View this article via: CrossRef PubMed Google Scholar

Rumah KR, et al. The myelin and lymphocyte protein MAL is required for binding and activity of Clostridium perfringens ε-Toxin. PLoS Pathog. 2015;11(5):e1004896.
View this article via: CrossRef PubMed Google Scholar

Linden JR, et al. Clostridium perfringens epsilon toxin causes selective death of mature oligodendrocytes and central nervous system demyelination. mBio. 2015;6(3):e02513.
View this article via: PubMed Google Scholar

Adler D, et al. Clostridium perfringens epsilon toxin compromises the blood-brain barrier in a humanized zebrafish model. iScience. 2019;15:39–54.
View this article via: CrossRef PubMed Google Scholar

Rumah KR, et al. Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease. PLoS One. 2013;8(10):e76359.
View this article via: CrossRef PubMed Google Scholar

Blanch M, et al. The Cytotoxicity of epsilon toxin from clostridium perfringens on lymphocytes is mediated by MAL protein expression. Mol Cell Biol. 2018;38(19):e00086-18.
View this article via: PubMed Google Scholar

Robertson SL, et al. Evidence for a prepore stage in the action of Clostridium perfringens epsilon toxin. PLoS One. 2011;6(7):e22053.
View this article via: CrossRef PubMed Google Scholar

Knapp O, et al. Residues involved in the pore-forming activity of the Clostridium perfringens iota toxin. Cell Microbiol. 2015;17(2):288–302.
View this article via: CrossRef PubMed Google Scholar

Miyata S, et al. Clostridium perfringens epsilon-toxin forms a heptameric pore within the detergent-insoluble microdomains of Madin-Darby canine kidney cells and rat synaptosomes. J Biol Chem. 2002;277(42):39463–39468.
View this article via: CrossRef PubMed Google Scholar

Mander KA, Finnie JW. Loss of endothelial barrier antigen immunoreactivity in rat retinal microvessels is correlated with Clostridium perfringens type D Epsilon toxin-induced damage to the blood-retinal barrier. J Comp Pathol. 2018;158:51–55.
View this article via: CrossRef PubMed Google Scholar

Zhu C, et al. Clostridium perfringens prototoxin-induced alteration of endothelial barrier antigen (EBA) immunoreactivity at the blood-brain barrier (BBB). Exp Neurol. 2001;169(1):72–82.
View this article via: CrossRef PubMed Google Scholar

Finnie JW, Hajduk P. An immunohistochemical study of plasma albumin extravasation in the brain of mice after the administration of Clostridium perfringens type D epsilon toxin. Aust Vet J. 1992;69(10):261–262.
View this article via: CrossRef PubMed Google Scholar

Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.
View this article via: CrossRef PubMed Google Scholar

Carman RJ, et al. Clostridium perfringens toxin genotypes in the feces of healthy North Americans. Anaerobe. 2008;14(2):102–108.
View this article via: CrossRef PubMed Google Scholar

Li J, et al. Sialidases affect the host cell adherence and epsilon toxin-induced cytotoxicity of Clostridium perfringens type D strain CN3718. PLoS Pathog. 2011;7(12):e1002429.
View this article via: CrossRef PubMed Google Scholar

Allaband C, et al. Microbiome 101: studying, analyzing, and interpreting gut microbiome data for clinicians. Clin Gastroenterol Hepatol. 2019;17(2):218–230.
View this article via: CrossRef PubMed Google Scholar

Eckburg PB, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–1638.
View this article via: CrossRef PubMed Google Scholar

Hevia A, et al. Application of density gradient for the isolation of the fecal microbial stool component and the potential use thereof. Sci Rep. 2015;5:16807.
View this article via: CrossRef PubMed Google Scholar

Wagley S, et al. Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis. Mult Scler. 2019;25(5):653–660.
View this article via: CrossRef PubMed Google Scholar

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
View this article via: CrossRef PubMed Google Scholar

Popoff MR. Clostridial pore-forming toxins: powerful virulence factors. Anaerobe. 2014;30:220–238.
View this article via: CrossRef PubMed Google Scholar

Nagpal R, et al. Sensitive quantification of Clostridium perfringens in human feces by quantitative real-time PCR targeting alpha-toxin and enterotoxin genes. BMC Microbiol. 2015;15:219.
View this article via: CrossRef PubMed Google Scholar

Hughes ML, et al. Epsilon-toxin plasmids of Clostridium perfringens type D are conjugative. J Bacteriol. 2007;189(21):7531–7538.
View this article via: CrossRef PubMed Google Scholar

Li J, et al. Toxin plasmids of Clostridium perfringens. Microbiol Mol Biol Rev. 2013;77(2):208–233.
View this article via: CrossRef Google Scholar

Revitt-Mills SA, et al. The ever-expanding tcp conjugation locus of pCW3 from Clostridium perfringens. Plasmid. 2021;113:102516.
View this article via: CrossRef PubMed Google Scholar

Adams V, et al. Plasmid partitioning systems of conjugative plasmids from Clostridium perfringens. Plasmid. 2015;80:90–96.
View this article via: CrossRef PubMed Google Scholar

Murrell TG, et al. A review of the sheep-multiple sclerosis connection. Med Hypotheses. 1986;19(1):27–39.
View this article via: CrossRef PubMed Google Scholar

Miyamoto K, et al. Sequencing and diversity analyses reveal extensive similarities between some epsilon-toxin-encoding plasmids and the pCPF5603 Clostridium perfringens enterotoxin plasmid. J Bacteriol. 2008;190(21):7178–7188.
View this article via: CrossRef PubMed Google Scholar

Linden JR, et al. A novel panel of rabbit monoclonal antibodies and their diverse applications including inhibition of Clostridium perfringens epsilon toxin oligomerization. Antibodies (Basel). 2018;7(4):37.
View this article via: CrossRef PubMed Google Scholar

Waturuocha UW, et al. A low-prevalence single-nucleotide polymorphism in the sensor kinase PhoR in Mycobacterium tuberculosis suppresses its autophosphatase activity and reduces pathogenic fitness: implications in evolutionary selection. Front Microbiol. 2021;12:724482.
View this article via: CrossRef PubMed Google Scholar

Weissman SJ, et al. Enterobacterial adhesins and the case for studying SNPs in bacteria. Trends Microbiol. 2003;11(3):115–117.
View this article via: CrossRef PubMed Google Scholar

Mahamat Abdelrahim A, et al. Large-scale genomic analyses and toxinotyping of Clostridium perfringens implicated in foodborne outbreaks in France. Front Microbiol. 2019;10:777.
View this article via: CrossRef Google Scholar

Lacey JA, et al. Whole genome analysis reveals the diversity and evolutionary relationships between necrotic enteritis-causing strains of Clostridium perfringens. BMC Genomics. 2018;19(1):379.
View this article via: CrossRef PubMed Google Scholar

Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet. 2011;12(10):683–691.
View this article via: CrossRef PubMed Google Scholar

Wekerle H, Lassmann H. The immunology of inflammatory demyelinating disease. In: Compston A, et al., eds. McAlpine’s Multiple Sclerosis (4th Edition). Churchill Livingstone; 2006:491–555.

Walker LS, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol. 2002;2(1):11–19.
View this article via: CrossRef PubMed Google Scholar

Carson MJ, et al. CNS immune privilege: hiding in plain sight. Immunol Rev. 2006;213:48–65.
View this article via: CrossRef PubMed Google Scholar

Engelhardt B, et al. The movers and shapers in immune privilege of the CNS. Nat Immunol. 2017;18(2):123–131.
View this article via: CrossRef PubMed Google Scholar

Laaker C, et al. Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc. 2021;1(12):e300.
View this article via: PubMed Google Scholar

Richard JF, et al. Crawling phagocytes recruited in the brain vasculature after pertussis toxin exposure through IL6, ICAM1 and ITGαM. Brain Pathol. 2011;21(6):661–671.
View this article via: CrossRef PubMed Google Scholar

Schellenberg AE, et al. Blood-brain barrier disruption in CCL2 transgenic mice during pertussis toxin-induced brain inflammation. Fluids Barriers CNS. 2012;9(1):10.
View this article via: CrossRef PubMed Google Scholar

Bettelli E, et al. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med. 2003;197(9):1073–1081.
View this article via: CrossRef PubMed Google Scholar

Millan J, Alonso MA. MAL, a novel integral membrane protein of human T lymphocytes, associates with glycosylphosphatidylinositol-anchored proteins and Src-like tyrosine kinases. Eur J Immunol. 1998;28(11):3675–3684.
View this article via: CrossRef PubMed Google Scholar

Pape KA, et al. Use of adoptive transfer of T-cell-antigen-receptor-transgenic T cell for the study of T-cell activation in vivo. Immunol Rev. 1997;156:67–78.
View this article via: CrossRef PubMed Google Scholar

Moon JJ, et al. Tracking epitope-specific T cells. Nat Protoc. 2009;4(4):565–581.
View this article via: CrossRef Google Scholar

Ronchi F, et al. Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1β production by myeloid cells. Nat Commun. 2016;7:11541.
View this article via: CrossRef PubMed Google Scholar

Pulido RS, et al. Neuronal activity regulates blood-brain barrier efflux transport through endothelial circadian genes. Neuron. 2020;108(5):937–952.
View this article via: CrossRef PubMed Google Scholar

Law CW, et al. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15(2):R29.
View this article via: CrossRef PubMed Google Scholar

Munji RN, et al. Profiling the mouse brain endothelial transcriptome in health and disease models reveals a core blood-brain barrier dysfunction module. Nat Neurosci. 2019;22(11):1892–1902.
View this article via: CrossRef PubMed Google Scholar

Cree BA, et al. Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens. Ann Neurol. 2016;80(3):443–447.
View this article via: CrossRef PubMed Google Scholar

Zamvil SS, et al. The gut microbiome in neuromyelitis optica. Neurotherapeutics. 2018;15(1):92–101.
View this article via: CrossRef Google Scholar

Garcia JP, et al. Epsilon toxin is essential for the virulence of Clostridium perfringens type D infection in sheep, goats, and mice. Infect Immun. 2013;81(7):2405–2414.
View this article via: CrossRef PubMed Google Scholar

Songer JG. Clostridial enteric diseases of domestic animals. Clin Microbiol Rev. 1996;9(2):216–234.
View this article via: CrossRef PubMed Google Scholar

Uzal FAG, et al. Diseases produced by Clostridium perfringens type D. In: Uzal FA, et al. eds. Clostridial Diseases of Animals. Wiley-Blackwell; 2016:157–172.

Finnie JW. Neurological disorders produced by Clostridium perfringens type D epsilon toxin. Anaerobe. 2004;10(2):145–150.
View this article via: CrossRef PubMed Google Scholar

Bjornevik K, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296–301.
View this article via: CrossRef Google Scholar

Lanz TV, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321–327.
View this article via: CrossRef Google Scholar

Winter JR, et al. Predictors of Epstein-Barr virus serostatus in young people in England. BMC Infect Dis. 2019;19(1):1007.
View this article via: CrossRef PubMed Google Scholar

Horwitz RI, et al. Falling down the biological rabbit hole: Epstein-Barr virus, biography, and multiple sclerosis. J Clin Invest. 2022;132(17):e164141.
View this article via: JCI CrossRef PubMed Google Scholar

Nathan C. Nonresolving inflammation redux. Immunity. 2022;55(4):592–605.
View this article via: CrossRef PubMed Google Scholar

Edgar R, Domrachev M, Lash AEGene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–210.
View this article via: CrossRef PubMed Google Scholar

[1] Dawson J. The histology of disseminated sclerosis. Trans Roy Soc Edin. 1916;50:517–740.
View this article via: CrossRef PubMed Google Scholar

[2] Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Perspect Med. 2018;8(3):a028936.
View this article via: CrossRef PubMed Google Scholar

[3] Absinta M, et al. Direct MRI detection of impending plaque development in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2015;2(5):e145.
View this article via: CrossRef PubMed Google Scholar

[4] Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol. 2004;55(4):458–468.
View this article via: CrossRef PubMed Google Scholar

[5] Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol. 2004;3(12):709–718.
View this article via: CrossRef PubMed Google Scholar

[6] Thompson AJ, et al. Multiple sclerosis. Lancet. 2018;391(10130):1622–1636.
View this article via: CrossRef Google Scholar

[7] Miyauchi E, et al. The impact of the gut microbiome on extra-intestinal autoimmune diseases. Nat Rev Immunol. 2022;23(1):9–23.
View this article via: PubMed Google Scholar

[8] Jangi S, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016;7:12015.
View this article via: CrossRef PubMed Google Scholar

[9] Berer K, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A. 2017;114(40):10719–10724.
View this article via: CrossRef PubMed Google Scholar

[10] Chen J, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6:28484.
View this article via: CrossRef PubMed Google Scholar

[11] Cosorich I, et al. High frequency of intestinal T_H17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Sci Adv. 2017;3(7):e1700492.
View this article via: CrossRef PubMed Google Scholar

[12] Cekanaviciute E, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A. 2017;114(40):10713–10718.
View this article via: CrossRef Google Scholar

[13] Ventura RE, et al. Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course. Sci Rep. 2019;9(1):16396.
View this article via: CrossRef PubMed Google Scholar

[14] Mirza A, et al. The multiple sclerosis gut microbiota: a systematic review. Mult Scler Relat Disord. 2020;37:101427.
View this article via: CrossRef Google Scholar

[15] Cantoni C, et al. Alterations of host-gut microbiome interactions in multiple sclerosis. EBioMedicine. 2022;76:103798.
View this article via: CrossRef Google Scholar

[16] Ghezzi L, et al. Targeting the gut to treat multiple sclerosis. J Clin Invest. 2021;131(13):e143774.
View this article via: JCI CrossRef PubMed Google Scholar

[17] Miyake S, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters. PLoS One. 2015;10(9):e0137429.
View this article via: CrossRef PubMed Google Scholar

[18] Mirza AI, et al. The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. Mult Scler Relat Disord. 2022;63:103829.
View this article via: CrossRef PubMed Google Scholar

[19] iMSMS Consortium. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell. 2022;185(19):3467–3486.
View this article via: CrossRef PubMed Google Scholar

[20] Wekerle H. Nature, nurture, and microbes: The development of multiple sclerosis. Acta Neurol Scand. 2017;136 Suppl 201:22–25.
View this article via: CrossRef PubMed Google Scholar

[21] Rothhammer V, et al. Microglial control of astrocytes in response to microbial metabolites. Nature. 2018;557(7707):724–728.
View this article via: CrossRef PubMed Google Scholar

[22] Rothhammer V, et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med. 2016;22(6):586–597.
View this article via: CrossRef PubMed Google Scholar

[23] Miyauchi E, et al. Gut microorganisms act together to exacerbate inflammation in spinal cords. Nature. 2020;585(7823):102–106.
View this article via: CrossRef PubMed Google Scholar

[24] Schnell A, et al. Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunity. Cell. 2021;184(26):6281–6298.
View this article via: CrossRef PubMed Google Scholar

[25] Sanmarco LM, et al. Gut-licensed IFNgamma(+) NK cells drive LAMP1(+)TRAIL(+) anti-inflammatory astrocytes. Nature. 2021;590(7846):473–479.
View this article via: CrossRef PubMed Google Scholar

[26] Linden JR, et al. Clostridium perfringens epsilon toxin induces blood brain barrier permeability via caveolae-dependent transcytosis and requires expression of MAL. PLoS Pathog. 2019;15(11):e1008014.
View this article via: CrossRef PubMed Google Scholar

[27] Rood JI, et al. Expansion of the Clostridium perfringens toxin-based typing scheme. Anaerobe. 2018;53:5–10.
View this article via: CrossRef PubMed Google Scholar

[28] Chen J, et al. Host cell-induced signaling causes Clostridium perfringens to upregulate production of toxins important for intestinal infections. Gut Microbes. 2014;5(1):96–107.
View this article via: CrossRef PubMed Google Scholar

[29] Chen J, McClane BA. Role of the Agr-like quorum-sensing system in regulating toxin production by Clostridium perfringens type B strains CN1793 and CN1795. Infect Immun. 2012;80(9):3008–3017.
View this article via: CrossRef PubMed Google Scholar

[30] Sayeed S, et al. Epsilon-toxin is required for most Clostridium perfringens type D vegetative culture supernatants to cause lethality in the mouse intravenous injection model. Infect Immun. 2005;73(11):7413–7421.
View this article via: CrossRef PubMed Google Scholar

[31] Goldstein MR, et al. Detection and characterization of Clostridium perfringens in the feces of healthy and diarrheic dogs. Can J Vet Res. 2012;76(3):161–165.
View this article via: PubMed Google Scholar

[32] Regan SB, et al. Identification of epsilon toxin-producing Clostridium perfringens strains in American retail food. Anaerobe. 2018;54:124–127.
View this article via: CrossRef PubMed Google Scholar

[33] Anwar Z, et al. Enrichment and detection of clostridium perfringens toxinotypes in retail food samples. J Vis Exp. 2019;(152).
View this article via: PubMed Google Scholar

[34] Lee CA, Labbe R. Distribution of enterotoxin- and epsilon-positive clostridium perfringens spores in U.S. Retail spices. J Food Prot. 2018;81(3):394–399.
View this article via: CrossRef Google Scholar

[35] Madden RH, et al. Clostridium perfringens as an indicator of hygienic quality of depurated shellfish. J Food Prot. 1986;49(1):33–36.
View this article via: CrossRef PubMed Google Scholar

[36] Davies CM, et al. Survival of fecal microorganisms in marine and freshwater sediments. Appl Environ Microbiol. 1995;61(5):1888–1896.
View this article via: CrossRef PubMed Google Scholar

[37] Miller WA, et al. Salmonella spp., Vibrio spp., Clostridium perfringens, and Plesiomonas shigelloides in marine and freshwater invertebrates from coastal California ecosystems. Microb Ecol. 2006;52(2):198–206.
View this article via: CrossRef PubMed Google Scholar

[38] Skanavis C, Yanko WA. Clostridium perfringens as a potential indicator for the presence of sewage solids in marine sediments. Mar Pollut Bull. 2001;42(1):31–35.
View this article via: CrossRef PubMed Google Scholar

[39] Wade TJ, et al. Rapidly measured indicators of recreational water quality and swimming-associated illness at marine beaches: a prospective cohort study. Environ Health. 2010;9:66.
View this article via: CrossRef PubMed Google Scholar

[40] Li J, et al. Prevalence of enterotoxigenic Clostridium perfringens Isolates in Pittsburgh (Pennsylvania) area soils and home kitchens. Appl Environ Microbiol. 2007;73(22):7218–7224.
View this article via: CrossRef PubMed Google Scholar

[41] Drean P, et al. Characterization of the spore-forming Bacillus cereus sensu lato group and Clostridium perfringens bacteria isolated from the Australian dairy farm environment. BMC Microbiol. 2015;15:38.
View this article via: CrossRef PubMed Google Scholar

[42] Strong DH, et al. Incidence of Clostridium perfringens in American foods. Appl Microbiol. 1963;11(1):42–44.
View this article via: CrossRef PubMed Google Scholar

[43] Wen Q, McClane BA. Detection of enterotoxigenic Clostridium perfringens type A isolates in American retail foods. Appl Environ Microbiol. 2004;70(5):2685–2691.
View this article via: CrossRef PubMed Google Scholar

[44] Talukdar PK, et al. Inactivation strategies for clostridium perfringens spores and vegetative cells. Appl Environ Microbiol. 2017;83(1):e02731-16.
View this article via: PubMed Google Scholar

[45] Talukdar PK, et al. Updates on the sporulation process in Clostridium species. Res Microbiol. 2015;166(4):225–235.
View this article via: CrossRef PubMed Google Scholar

[46] Hatheway CL. Toxigenic clostridia. Clin Microbiol Rev. 1990;3(1):66–98.
View this article via: CrossRef Google Scholar

[47] Hildebrand F, et al. Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. Genome Biol. 2013;14(1):R4.
View this article via: CrossRef PubMed Google Scholar

[48] Bokori-Brown M, et al. Molecular basis of toxicity of Clostridium perfringens epsilon toxin. FEBS J. 2011;278(23):4589–4601.
View this article via: CrossRef PubMed Google Scholar

[49] Savva CG, et al. The pore structure of Clostridium perfringens epsilon toxin. Nat Commun. 2019;10(1):2641.
View this article via: CrossRef PubMed Google Scholar

[50] Popoff MR. Epsilon toxin: a fascinating pore-forming toxin. FEBS J. 2011;278(23):4602–4615.
View this article via: CrossRef PubMed Google Scholar

[51] Freedman JC, et al. Proteolytic processing and activation of Clostridium perfringens epsilon toxin by caprine small intestinal contents. mBio. 2014;5(5):e01994–e01914.
View this article via: PubMed Google Scholar

[52] Harkness JM, et al. Identification of a lambda toxin-negative Clostridium perfringens strain that processes and activates epsilon prototoxin intracellularly. Anaerobe. 2012;18(5):546–552.
View this article via: CrossRef PubMed Google Scholar

[53] Goldstein J, et al. Clostridium perfringens epsilon toxin increases the small intestinal permeability in mice and rats. PLoS One. 2009;4(9):e7065.
View this article via: CrossRef PubMed Google Scholar

[54] Rumah KR, et al. The myelin and lymphocyte protein MAL is required for binding and activity of Clostridium perfringens ε-Toxin. PLoS Pathog. 2015;11(5):e1004896.
View this article via: CrossRef PubMed Google Scholar

[55] Linden JR, et al. Clostridium perfringens epsilon toxin causes selective death of mature oligodendrocytes and central nervous system demyelination. mBio. 2015;6(3):e02513.
View this article via: PubMed Google Scholar

[56] Adler D, et al. Clostridium perfringens epsilon toxin compromises the blood-brain barrier in a humanized zebrafish model. iScience. 2019;15:39–54.
View this article via: CrossRef PubMed Google Scholar

[57] Rumah KR, et al. Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease. PLoS One. 2013;8(10):e76359.
View this article via: CrossRef PubMed Google Scholar

[58] Blanch M, et al. The Cytotoxicity of epsilon toxin from clostridium perfringens on lymphocytes is mediated by MAL protein expression. Mol Cell Biol. 2018;38(19):e00086-18.
View this article via: PubMed Google Scholar

[59] Robertson SL, et al. Evidence for a prepore stage in the action of Clostridium perfringens epsilon toxin. PLoS One. 2011;6(7):e22053.
View this article via: CrossRef PubMed Google Scholar

[60] Knapp O, et al. Residues involved in the pore-forming activity of the Clostridium perfringens iota toxin. Cell Microbiol. 2015;17(2):288–302.
View this article via: CrossRef PubMed Google Scholar

[61] Miyata S, et al. Clostridium perfringens epsilon-toxin forms a heptameric pore within the detergent-insoluble microdomains of Madin-Darby canine kidney cells and rat synaptosomes. J Biol Chem. 2002;277(42):39463–39468.
View this article via: CrossRef PubMed Google Scholar

[62] Mander KA, Finnie JW. Loss of endothelial barrier antigen immunoreactivity in rat retinal microvessels is correlated with Clostridium perfringens type D Epsilon toxin-induced damage to the blood-retinal barrier. J Comp Pathol. 2018;158:51–55.
View this article via: CrossRef PubMed Google Scholar

[63] Zhu C, et al. Clostridium perfringens prototoxin-induced alteration of endothelial barrier antigen (EBA) immunoreactivity at the blood-brain barrier (BBB). Exp Neurol. 2001;169(1):72–82.
View this article via: CrossRef PubMed Google Scholar

[64] Finnie JW, Hajduk P. An immunohistochemical study of plasma albumin extravasation in the brain of mice after the administration of Clostridium perfringens type D epsilon toxin. Aust Vet J. 1992;69(10):261–262.
View this article via: CrossRef PubMed Google Scholar

[65] Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.
View this article via: CrossRef PubMed Google Scholar

[66] Carman RJ, et al. Clostridium perfringens toxin genotypes in the feces of healthy North Americans. Anaerobe. 2008;14(2):102–108.
View this article via: CrossRef PubMed Google Scholar

[67] Li J, et al. Sialidases affect the host cell adherence and epsilon toxin-induced cytotoxicity of Clostridium perfringens type D strain CN3718. PLoS Pathog. 2011;7(12):e1002429.
View this article via: CrossRef PubMed Google Scholar

[68] Allaband C, et al. Microbiome 101: studying, analyzing, and interpreting gut microbiome data for clinicians. Clin Gastroenterol Hepatol. 2019;17(2):218–230.
View this article via: CrossRef PubMed Google Scholar

[69] Eckburg PB, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–1638.
View this article via: CrossRef PubMed Google Scholar

[70] Hevia A, et al. Application of density gradient for the isolation of the fecal microbial stool component and the potential use thereof. Sci Rep. 2015;5:16807.
View this article via: CrossRef PubMed Google Scholar

[71] Wagley S, et al. Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis. Mult Scler. 2019;25(5):653–660.
View this article via: CrossRef PubMed Google Scholar

[72] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
View this article via: CrossRef PubMed Google Scholar

[73] Popoff MR. Clostridial pore-forming toxins: powerful virulence factors. Anaerobe. 2014;30:220–238.
View this article via: CrossRef PubMed Google Scholar

[74] Nagpal R, et al. Sensitive quantification of Clostridium perfringens in human feces by quantitative real-time PCR targeting alpha-toxin and enterotoxin genes. BMC Microbiol. 2015;15:219.
View this article via: CrossRef PubMed Google Scholar

[75] Hughes ML, et al. Epsilon-toxin plasmids of Clostridium perfringens type D are conjugative. J Bacteriol. 2007;189(21):7531–7538.
View this article via: CrossRef PubMed Google Scholar

[76] Li J, et al. Toxin plasmids of Clostridium perfringens. Microbiol Mol Biol Rev. 2013;77(2):208–233.
View this article via: CrossRef Google Scholar

[77] Revitt-Mills SA, et al. The ever-expanding tcp conjugation locus of pCW3 from Clostridium perfringens. Plasmid. 2021;113:102516.
View this article via: CrossRef PubMed Google Scholar

[78] Adams V, et al. Plasmid partitioning systems of conjugative plasmids from Clostridium perfringens. Plasmid. 2015;80:90–96.
View this article via: CrossRef PubMed Google Scholar

[79] Murrell TG, et al. A review of the sheep-multiple sclerosis connection. Med Hypotheses. 1986;19(1):27–39.
View this article via: CrossRef PubMed Google Scholar

[80] Miyamoto K, et al. Sequencing and diversity analyses reveal extensive similarities between some epsilon-toxin-encoding plasmids and the pCPF5603 Clostridium perfringens enterotoxin plasmid. J Bacteriol. 2008;190(21):7178–7188.
View this article via: CrossRef PubMed Google Scholar

[81] Linden JR, et al. A novel panel of rabbit monoclonal antibodies and their diverse applications including inhibition of Clostridium perfringens epsilon toxin oligomerization. Antibodies (Basel). 2018;7(4):37.
View this article via: CrossRef PubMed Google Scholar

[82] Waturuocha UW, et al. A low-prevalence single-nucleotide polymorphism in the sensor kinase PhoR in Mycobacterium tuberculosis suppresses its autophosphatase activity and reduces pathogenic fitness: implications in evolutionary selection. Front Microbiol. 2021;12:724482.
View this article via: CrossRef PubMed Google Scholar

[83] Weissman SJ, et al. Enterobacterial adhesins and the case for studying SNPs in bacteria. Trends Microbiol. 2003;11(3):115–117.
View this article via: CrossRef PubMed Google Scholar

[84] Mahamat Abdelrahim A, et al. Large-scale genomic analyses and toxinotyping of Clostridium perfringens implicated in foodborne outbreaks in France. Front Microbiol. 2019;10:777.
View this article via: CrossRef Google Scholar

[85] Lacey JA, et al. Whole genome analysis reveals the diversity and evolutionary relationships between necrotic enteritis-causing strains of Clostridium perfringens. BMC Genomics. 2018;19(1):379.
View this article via: CrossRef PubMed Google Scholar

[86] Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet. 2011;12(10):683–691.
View this article via: CrossRef PubMed Google Scholar

[87] Wekerle H, Lassmann H. The immunology of inflammatory demyelinating disease. In: Compston A, et al., eds. McAlpine’s Multiple Sclerosis (4th Edition). Churchill Livingstone; 2006:491–555.

[88] Walker LS, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol. 2002;2(1):11–19.
View this article via: CrossRef PubMed Google Scholar

[89] Carson MJ, et al. CNS immune privilege: hiding in plain sight. Immunol Rev. 2006;213:48–65.
View this article via: CrossRef PubMed Google Scholar

[90] Engelhardt B, et al. The movers and shapers in immune privilege of the CNS. Nat Immunol. 2017;18(2):123–131.
View this article via: CrossRef PubMed Google Scholar

[91] Laaker C, et al. Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc. 2021;1(12):e300.
View this article via: PubMed Google Scholar

[92] Richard JF, et al. Crawling phagocytes recruited in the brain vasculature after pertussis toxin exposure through IL6, ICAM1 and ITGαM. Brain Pathol. 2011;21(6):661–671.
View this article via: CrossRef PubMed Google Scholar

[93] Schellenberg AE, et al. Blood-brain barrier disruption in CCL2 transgenic mice during pertussis toxin-induced brain inflammation. Fluids Barriers CNS. 2012;9(1):10.
View this article via: CrossRef PubMed Google Scholar

[94] Bettelli E, et al. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med. 2003;197(9):1073–1081.
View this article via: CrossRef PubMed Google Scholar

[95] Millan J, Alonso MA. MAL, a novel integral membrane protein of human T lymphocytes, associates with glycosylphosphatidylinositol-anchored proteins and Src-like tyrosine kinases. Eur J Immunol. 1998;28(11):3675–3684.
View this article via: CrossRef PubMed Google Scholar

[96] Pape KA, et al. Use of adoptive transfer of T-cell-antigen-receptor-transgenic T cell for the study of T-cell activation in vivo. Immunol Rev. 1997;156:67–78.
View this article via: CrossRef PubMed Google Scholar

[97] Moon JJ, et al. Tracking epitope-specific T cells. Nat Protoc. 2009;4(4):565–581.
View this article via: CrossRef Google Scholar

[98] Ronchi F, et al. Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1β production by myeloid cells. Nat Commun. 2016;7:11541.
View this article via: CrossRef PubMed Google Scholar

[99] Pulido RS, et al. Neuronal activity regulates blood-brain barrier efflux transport through endothelial circadian genes. Neuron. 2020;108(5):937–952.
View this article via: CrossRef PubMed Google Scholar

[100] Law CW, et al. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15(2):R29.
View this article via: CrossRef PubMed Google Scholar

[101] Munji RN, et al. Profiling the mouse brain endothelial transcriptome in health and disease models reveals a core blood-brain barrier dysfunction module. Nat Neurosci. 2019;22(11):1892–1902.
View this article via: CrossRef PubMed Google Scholar

[102] Cree BA, et al. Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens. Ann Neurol. 2016;80(3):443–447.
View this article via: CrossRef PubMed Google Scholar

[103] Zamvil SS, et al. The gut microbiome in neuromyelitis optica. Neurotherapeutics. 2018;15(1):92–101.
View this article via: CrossRef Google Scholar

[104] Garcia JP, et al. Epsilon toxin is essential for the virulence of Clostridium perfringens type D infection in sheep, goats, and mice. Infect Immun. 2013;81(7):2405–2414.
View this article via: CrossRef PubMed Google Scholar

[105] Songer JG. Clostridial enteric diseases of domestic animals. Clin Microbiol Rev. 1996;9(2):216–234.
View this article via: CrossRef PubMed Google Scholar

[106] Uzal FAG, et al. Diseases produced by Clostridium perfringens type D. In: Uzal FA, et al. eds. Clostridial Diseases of Animals. Wiley-Blackwell; 2016:157–172.

[107] Finnie JW. Neurological disorders produced by Clostridium perfringens type D epsilon toxin. Anaerobe. 2004;10(2):145–150.
View this article via: CrossRef PubMed Google Scholar

[108] Bjornevik K, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296–301.
View this article via: CrossRef Google Scholar

[109] Lanz TV, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321–327.
View this article via: CrossRef Google Scholar

[110] Winter JR, et al. Predictors of Epstein-Barr virus serostatus in young people in England. BMC Infect Dis. 2019;19(1):1007.
View this article via: CrossRef PubMed Google Scholar

[111] Horwitz RI, et al. Falling down the biological rabbit hole: Epstein-Barr virus, biography, and multiple sclerosis. J Clin Invest. 2022;132(17):e164141.
View this article via: JCI CrossRef PubMed Google Scholar

[112] Nathan C. Nonresolving inflammation redux. Immunity. 2022;55(4):592–605.
View this article via: CrossRef PubMed Google Scholar

[113] Edgar R, Domrachev M, Lash AEGene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–210.
View this article via: CrossRef PubMed Google Scholar

Epsilon toxin–producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege

Related article:

Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models

Article tools

Metrics

Go to

Epsilon toxin–producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege

Related article:

Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models

Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models

Abstract

Authors

Article tools

Metrics

Go to

Sign up for email alerts